check_circleStudy Completed

Prevention of venous thromboembolism after MOS

BAY59-7939, Characterization of oral solution

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

18 - 55 Years
  • -

  • -

Trial summary

Enrollment Goal
17
Trial Dates
September 2009 - December 2009
Phase
Phase 1
Could I Receive a placebo
N/A
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteer
N/A

Where to participate

StatusInstitutionLocation
Completed
Bayer HealthCareWuppertal, 42096, Germany

Trial design

Single-dose, open-label, randomized, 4-way crossover study to compare 10 and 20 mg of an oral suspension of rivaroxaban under fasting and 20 mg of an oral suspension of rivaroxaban under fed conditions to 10 mg of an immediate release tablet under fasting conditions in healthy subjects
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A